Long-term survival in chronic myelocytic leukemia after a first primary malignancy.
Within the past 10-15 years, major advances in therapy have strongly improved prognosis of patients with chronic myelocytic leukaemia (CML). We estimated trends in 5- and 10-year relative survival of patients developing CML after a previous malignancy in the United States from 1990-1994 to 2000-2004. Period analysis was employed to disclose recent developments with minimum delay. Overall, 5- and 10-year relative survival increased from 17.6% to 37.7% (p<0.0001) and from 7.6% to 23.8% (p<0.0001), respectively. Improvements were particularly strong in younger age groups. Prognosis of CML patients with previous malignancy no longer lags behind prognosis of patients with primary CML.
Brenner
Hermann
H
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Str. 20, D-69115 Heidelberg, Germany. h.brenner@dkfz-heidelberg.de
Gondos
Adam
A
Pulte
Dianne
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000473:pathology*; D016019:Survival Analysis; D055815:Young Adult